Intellipharmaceutics International Inc
TSX:IPCI
Intellipharmaceutics International Inc
TSX:IPCI
Price:
0.08
CAD
Market Cap:
CA$2.8m
Balance Sheet
Balance Sheet Decomposition
Intellipharmaceutics International Inc
Intellipharmaceutics International Inc
Balance Sheet Decomposition is not available for
Intellipharmaceutics International Inc
Intellipharmaceutics International Inc
Balance Sheet
Intellipharmaceutics International Inc
Intellipharmaceutics International Inc
Currency: USD
| Nov-2013 | Nov-2014 | Nov-2015 | Nov-2016 | Nov-2017 | Nov-2018 | Nov-2019 | Nov-2020 | Nov-2021 | Nov-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
1
|
4
|
2
|
4
|
2
|
7
|
0
|
0
|
1
|
0
|
|
| Cash |
1
|
4
|
2
|
4
|
2
|
7
|
0
|
0
|
1
|
0
|
|
| Total Receivables |
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
|
| Accounts Receivables |
1
|
1
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
3
|
6
|
3
|
6
|
4
|
9
|
2
|
1
|
1
|
0
|
|
| PP&E Net |
1
|
2
|
2
|
2
|
3
|
3
|
2
|
2
|
1
|
1
|
|
| PP&E Gross |
1
|
2
|
2
|
0
|
0
|
3
|
2
|
0
|
0
|
1
|
|
| Accumulated Depreciation |
3
|
3
|
4
|
0
|
0
|
5
|
6
|
0
|
0
|
7
|
|
| Other Long-Term Assets |
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
4
N/A
|
8
+80%
|
5
-34%
|
8
+53%
|
7
-7%
|
11
+55%
|
4
-67%
|
3
-11%
|
2
-38%
|
1
-32%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
1
|
3
|
1
|
2
|
3
|
4
|
4
|
4
|
4
|
|
| Accrued Liabilities |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
4
|
5
|
6
|
|
| Short-Term Debt |
2
|
1
|
2
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
5
|
3
|
5
|
4
|
5
|
5
|
7
|
10
|
10
|
12
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
5
|
0
|
0
|
3
|
2
|
2
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
10
N/A
|
3
-71%
|
5
+80%
|
7
+28%
|
7
+2%
|
7
+5%
|
7
+2%
|
10
+30%
|
10
+6%
|
12
+17%
|
|
| Equity | |||||||||||
| Common Stock |
12
|
19
|
21
|
30
|
35
|
44
|
46
|
46
|
49
|
49
|
|
| Retained Earnings |
42
|
45
|
53
|
63
|
72
|
86
|
94
|
97
|
102
|
105
|
|
| Additional Paid In Capital |
24
|
31
|
31
|
34
|
37
|
45
|
44
|
44
|
45
|
45
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
6
N/A
|
5
N/A
|
0
N/A
|
1
N/A
|
0
-65%
|
4
+951%
|
4
N/A
|
6
-71%
|
8
-29%
|
11
-30%
|
|
| Total Liabilities & Equity |
4
N/A
|
8
+80%
|
5
-34%
|
8
+53%
|
7
-7%
|
11
+55%
|
4
-67%
|
3
-11%
|
2
-38%
|
1
-32%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
2
|
2
|
2
|
3
|
3
|
18
|
22
|
24
|
33
|
33
|
|
Switch to:
Switch to:
See Also
Discover More
